Cost-utility analysis of dual-antibiotic cement versus single-antibiotic cement for the treatment of displaced intracapsular hip fractures in older adults
May Ee Png,Matt Costa,Agni Nickil,Juul Achten,Nicholas Peckham,Mike R Reed,WHiTE-8 Investigators,Andrew McAndrew,Sunit Patil,Mark Dunbar,Daniel Engelke,Mohammad Maqsood,Konstantinos Tsitskaris,Theophilus Joachim,Advait Jayant Gandhe,Ansar Mahmood,Russell Hawkins,Benedict Rogers,Sharad Bhatnagar,Kanthan Theivendran,Andrew Cattell,Inder Gill,Tim Chesser,Bryan Riemer,Ben Ollivere,Khitish Mohanty,David Melling,Ryan Wood,Toby Colegate-Stone,C P Charalambous,Chris Peach,Mark Farrar,Mike Reed,Graham Sleat,Ashwin Kulkarni,Rhys Clement,Iain McNamara,Yegappan Kalairajah,Gregoris Kambouroglou,Deepak Herlekar,Khushroo Suraliwala,Mohammad Faisal,Callum Clark,Sammy Hanna,Hemanta Das,Abdul Moeed,Alok Singh,Suranga Gurusinghe,Ashim Wokhlu,Lydia Jenner,Charlotte Lewis,Arham Qureshi,Andy Gazette,Shafiq Shahban,Kanai Garala,Chandramohan Sivagami Panneerselvam,Chris Bretherton,Alexander Martin,Mohamed Elmeligy,Breck Lord,James Archer,Omer Salar,Raghunaathan Rangan,Mohammed Shahid,Shakir Hussain,Vishnu Sharma,Angus Kaye,Imran Ullah,Farhan Syed,Ajay Chourasia,Neal Rupani,Euan Stirling,Sharon Scott,Simon Scott,Chris Roberts,Rachael Clegg,Ines Reichert,Amit Sharma,Anwar Khan,John Davison,Matthew Horner,Alexander Durst,Majeed Adel Shakokani,Ian Crowther,Benjamin Emmerson,Paul Rodham,Nickil Agni,Sabina Barbur,Wystan Lee Chevannes,Irfan Merchant,Ciaran Brennan,Benjamin Paul Kent,Ahmed M E Mostafa,Andrew King,Mukesh Madhavan,Andreas Panagiotopoulos,John Timothy Hirst,Simon Craxford,Wahid Abdul,Joshua Nadimi,Alexander Riddell,Anoop Anand,Christopher Jump,Anna Walsh,Kathryn Mcloughlin,Luke Hughes,Moataz El-Husseiny,Prashanth D’sa,Jacob Koris,Rebecca Morrell,Raj Gangadharan,Emily Flintoft,Amin Khieran,Laura Beddard,Stephanie Buchan,Joanne Lum
DOI: https://doi.org/10.1302/0301-620X.105B10.BJJ-2023-0633
2023-10-01
Abstract:Aims: To compare the cost-effectiveness of high-dose, dual-antibiotic cement versus single-antibiotic cement for the treatment of displaced intracapsular hip fractures in older adults. Methods: Using data from a multicentre randomized controlled trial (World Hip Trauma Evaluation 8 (WHiTE-8)) in the UK, a within-trial economic evaluation was conducted. Resource usage was measured over 120 days post randomization, and cost-effectiveness was reported in terms of incremental cost per quality-adjusted life year (QALY), gained from the UK NHS and personal social services (PSS) perspective in the base-case analysis. Methodological uncertainty was addressed using sensitivity analysis, while decision uncertainty was handled using confidence ellipses and cost-effectiveness acceptability curves. Results: The base-case analysis showed that high-dose, dual-antibiotic cement had a significantly higher mean cost (£224 (95% confidence interval (CI) -408 to 855)) and almost the same QALYs (0.001 (95% CI -0.002 to 0.003)) relative to single-antibiotic cement from the UK NHS and PSS perspective. The probability of the high-dose, dual-antibiotic cement being cost-effective was less than 0.3 at alternative cost-effectiveness thresholds, and its net monetary benefit was negative. This finding remained robust in the sensitivity analyses. Conclusion: This study shows that high-dose, dual-antibiotic cement is unlikely to be cost-effective compared to single-antibiotic cement for the treatment of displaced intracapsular hip fractures in older adults.